Social Media Ideas for Dbv Technologies

Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders

Attovia Therapeutics’ biologic medicines could offer advantages over currently available immune disorder drugs, such as Sanofi’s blockbuster medicine Dupixent. The IPO comes as Att...

As Food Allergy Treatments Become Big Business, Pharma Bets on VT-7208

Pharma is betting big on an experimental oral drug targeting BTK that is advancing toward Phase 2 trials for food allergy, chronic hives, and multiple sclerosis. The post As Food A...

Boulevard starts up with $65M to pursue targeted autoimmune drugs

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immu...

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

Can Peanut Allergy Be Changed in Infancy? DBV’s THRIVE Trial Tests a Bold New Approach

Researchers are testing whether starting peanut patch therapy in infancy can permanently change the course of peanut allergy. The post Can Peanut Allergy Be Changed in Infancy? DBV...

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment...

Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent

Attovia Therapeutics has filed for an IPO to secure funding for assets, including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

Precision BioSciences: Promising HBV Editing Evidence

Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO

Attovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a...

Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment

Galderma Group AG 2026 Q2 - Results - Earnings Call Presentation

Leo Pharma buys rare skin disease drug in $435M deal

Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.

Vaderis hauls in $152M to test an AKT-targeting drug

The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.

Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs

Boulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

Sanofi halts development of troubled immune drug in eczema

The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategi...

Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026

Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending

Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients as the Swiss biotech awaits an...

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Ta...

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months

Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claime...

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

Argenx Expands Immunology Portfolio with $2.2B Buyout of Forte Biosciences

Earlier this month Forte announced positive results for its lead candidate FB102, from a Phase Ib trial assessing the anti-CD122 monoclonal antibody in vitiligo. FB102 achieved a 2...